Previous close | 299.38 |
Open | 300.00 |
Bid | 285.00 x 800 |
Ask | 303.69 x 1000 |
Day's range | 293.39 - 303.40 |
52-week range | 193.11 - 314.00 |
Volume | |
Avg. volume | 2,967,843 |
Market cap | 286.378B |
Beta (5Y monthly) | 0.43 |
PE ratio (TTM) | 44.80 |
EPS (TTM) | 6.73 |
Earnings date | 04 Aug 2022 |
Forward dividend & yield | 3.92 (1.34%) |
Ex-dividend date | 13 May 2022 |
1y target est | 304.28 |
Shares of Eli Lilly (NYSE: LLY) rose on Monday after the U.S. Food and Drug Administration (FDA) approved the pharmaceutical giant's new diabetes treatment, tirzepatide. As of 1:50 p.m. ET, Eli Lilly's stock price was up more than 3%. A phase 3 clinical trial showed tirzepatide to reduce A1C -- a key measure of average blood sugar levels -- better than existing treatment options.
Lilly's (LLY) Mounjaro (tirzepatide) is a novel diabetes treatment, which has shown impressive blood sugar reductions and weight loss in a broad range of type II diabetes patients in the SURPASS studies.
Pfizer (PFE) is set to buy migraine drugmaker, Biohaven Pharmaceuticals for $11.6 billion. Bayer (BAYRY) beats Q1 earnings and sales expectations.